McShane, Lisa M.

Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)

McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005) · JNCI: Journal of the National Cancer Institute

Meta-analysis and systematic reviewsStatistical Methods in Epidemiology

Cited by 2,162

Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP Guideline update

Allison, K. H., Hammond, M. E. H., Dowsett, M., McKernin, S. E., Carey, L. A., Fitzgibbons, P. L., Hayes, D. F., Lakhani, S. R., Chavez-MacGregor, M., Perlmutter, J., et al. (2020) · Journal of Clinical Oncology

Breast Cancer Treatment StudiesBreast Lesions and Carcinomas

Cited by 1,574

REporting recommendations for tumour MARKer prognostic studies (REMARK).

for the Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics, McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005) · British Journal of Cancer

Meta-analysis and systematic reviewsStatistical Methods in Epidemiology

Cited by 1,394

Imaging biomarker roadmap for cancer studies

O'Connor, J. P. B., Aboagye, E. O., Adams, J. E., Aerts, H. J. W. L., Barrington, S. F., Beer, A. J., Boellaard, R., Bohndiek, S. E., Brady, M., Brown, G., et al. (2017) · Nature Reviews Clinical Oncology

Medical Imaging Techniques and ApplicationsRadiomics and Machine Learning in Medical Imaging

Cited by 1,091

Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)

Flaherty, K. T., Gray, R. J., Chen, A. P., Li, S., McShane, L. M., Patton, D., Hamilton, S. R., Williams, P. M., Iafrate, A. J., Sklar, J., et al. (2020) · Journal of Clinical Oncology

Cancer Genomics and DiagnosticsLung Cancer Treatments and Mutations

Cited by 294

Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q

Jhaveri, K. L., Wang, X. V., Makker, V., Luoh, S.-W., Mitchell, E. P., Zwiebel, J. A., Sharon, E., Gray, R. J., Li, S., McShane, L. M., et al. (2019) · Annals of Oncology

HER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations

Cited by 151

Generic Protocols for the Analytical Validation of Next-Generation Sequencing-Based ctDNA Assays: A Joint Consensus Recommendation of the BloodPAC’s Analytical Variables Working Group

Godsey, J. H., Silvestro, A., Barrett, J. C., Bramlett, K., Chudova, D., Deras, I., Dickey, J., Hicks, J., Johann, D. J., Leary, R., et al. (2020) · Clinical Chemistry

Cancer Genomics and DiagnosticsClinical Laboratory Practices and Quality Control

Cited by 104

Discussion: The Role, Position, and Function of the FDA—The Past, Present, and Future

Fleming, T. R., Demets, D. L., & McShane, L. M. (2017) · Biostatistics

Statistical Methods in Clinical TrialsHealthcare Regulation

Cited by 13